drugset / Trial / NCT01077284

Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones

NCT01077284

Phase 2 Completed 99 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the efficacy of febuxostat, once daily (QD), compared to allopurinol or placebo in patients with excessive amounts of uric acid in their urine and who have recently had kidney stones.

Timeline

Start
2010-02
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Allopurinol Small molecule 200 mg Oral
Comparator Allopurinol Small molecule 300 mg Oral
Subject Febuxostat Small molecule 80 mg Oral